Výsledky vyhledávání

Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis

Autor: Nick Thatcher, Kelvin Young, Victoria Soldatenkova, David R. Spigel, Gerrit Grau, Frances A. Shepherd, Javad Shahidi, Luis Paz-Ares, Raffael Kurek

Publikováno v: Thrombosis research. 167

Introduction Metastatic non-small cell lung cancer (NSCLC) is a recognized risk factor for VTE. Some systemic treatments may increase this risk further. Here, we present the risk of VTE and its prognostic significance for patients treated with chemot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e25c6dd4ba66c8cf613988687557333e
https://pubmed.ncbi.nlm.nih.gov/29787943

Zobrazit plný text záznamu

Rash management and treatment persistence of cancer patients treated with epidermal growth factor receptor inhibitors in the Truven MarketScan

Autor: Lei, Chen, Jacqueline, Brown, Dale Quentin, Marmaduke, Carlos, Mayo, Gerrit, Grau, Yiu-Keung, Lau, Coleman K, Obasaju

Publikováno v: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 26(7)

Rash toxicity is a common, expected class effect of epidermal growth factor receptor (EGFR) inhibitors. Although rash management is practiced, it is not well characterized in the real-world setting. We describe the management of rash that developed w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a610debf9466bedc5beba855e32a3e08
https://pubmed.ncbi.nlm.nih.gov/29423677

Zobrazit plný text záznamu

Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors

Autor: David Smith, Johan Wallin, Dale R. Shepard, James J. Lee, Archana Chaudhary, Raffael Kurek, Patricia LoRusso, John D. Powderly, Grace Chao, Malcolm I. Mitchell, Wee Teck Ng, Gerrit Grau

Publikováno v: Cancer chemotherapy and pharmacology. 78(2)

Necitumumab is a second-generation, recombinant, human immunoglobulin G1 monoclonal antibody that blocks the ligand binding site of the epidermal growth factor receptor. The primary objective of this phase 2 study, conducted in accordance with Intern

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20360bba522a4ea3752e128314853046
https://pubmed.ncbi.nlm.nih.gov/27312733

Zobrazit plný text záznamu

Hypomagnesaemia and its management following treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs): Results from 3 randomized studies of necitumumab (NECI) plus chemotherapy in first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC)

Autor: Shivani Nanda, David R. Gandara, Luis Paz-Ares, Javad Shahidi, Gerrit Grau, Mark A. Socinski, Nick Thatcher, Raffael Kurek, David R. Spigel, E. E. Vokes

Publikováno v: Annals of Oncology. 27:vi435

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8aa63451cdce24c9baea6d9e725c15a6
https://doi.org/10.1093/annonc/mdw383.56

Zobrazit plný text záznamu

Pooled analysis of venous thromboembolism (VTE) from four trials of necitumumab and chemotherapy for stage IV non-small cell lung cancer (NSCLC)

Autor: David R. Spigel, Victoria Soldatenkova, Kelvin Young, Javad Shahidi, Raffael Kurek, Nick Thatcher, Frances A. Shepherd, Gerrit Grau, Luis Paz-Ares

Publikováno v: Journal of Clinical Oncology. 34:e20534-e20534

e20534Background: Metastatic NSCLC is a recognized risk factor for VTE. Some systemic treatments may increase this risk further. Here, we present the risk of VTE and its prognostic significance in ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f292bd674a43ce691db82de06799a97c
https://doi.org/10.1200/jco.2016.34.15_suppl.e20534

Zobrazit plný text záznamu

Abstract A143: Treatment persistence and rash management of cancer patients treated with epidermal growth factor receptor inhibitors (EGFR-inhs) in Truven Marketscan Research Database

Autor: Carlos Mayo, Dale Quentin Marmaduke, Jaqueline Brown, Yiu-Keung Lau, Gerrit Grau, Lei Chen, Coleman K. Obasaju

Publikováno v: Molecular Cancer Therapeutics. 14:A143-A143

EGFR-inhs are treatment options for a number of cancer types and rash toxicity is a common and expected class effect of such treatments. Notably severe rash may lead to treatment discontinuation or dose modification. Although rash management is pract

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c16f9c6a932f39bf20886b00a4f55303
https://doi.org/10.1158/1535-7163.targ-15-a143

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání